Research progress on novel intraocular pressure lowering drugs using trabecular meshwork pathway
Glaucoma is a group of neurodegenerative diseases with pathological increase of intraocular pressure(IOP)as the main risk factor.Local use of IOP-lowering drugs is still the first line of treatment.Most of the aqueous humor flows out through the trabecular meshwork(TM)pathway,which is the main site of primary open-angle glaucoma.Therefore,novel IOP lowering drugs targeting the TM pathway are very important for the treatment of glaucoma.This article reviewed the mechanism and progress of Rho kinase inhibitors,nitric oxide donors and other novel IOP lowering drugs in recent years,aiming to provide clinical reference.
NETL
NSTL
万方数据
